Together, these results demonstrate that dual treatment leads to enhanced infiltration of CD4+ and CD8+ effector T cells, with elevated activation markers (elevated granzyme B, perforin and IFN-γ), as well as reduced Tregs in the tumour tissues. The gene discussed is CD8A; the disease is neoplasm.